Search - tctmd.com

Displaying 1 - 20 of 263

Sort: Relevancy | Date

Two Neutral IVUS Trials in Complex PCI—and One Positive—Spark Debate

News Conference News ACC 2026

Two Neutral IVUS Trials in Complex PCI—and One Positive—Spark Debate

April 02, 2026

Transcatheter ViV a Solid Option for Failed Mitral Bioprostheses: SURViV

News Conference News ACC 2026

Transcatheter ViV a Solid Option for Failed Mitral Bioprostheses: SURViV

March 30, 2026

Impella Support in High-Risk PCI Doesn’t Help, Might Harm: CHIP-BCIS3

News Conference News ACC 2026

Impella Support in High-Risk PCI Doesn’t Help, Might Harm: CHIP-BCIS3

Yael L. Maxwell

March 29, 2026

What’s Going to Be Hot at ACC 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

AI for Heart Failure Care Is Evolving Rapidly, THT 2026 Makes Clear

News Conference News THT 2026

AI for Heart Failure Care Is Evolving Rapidly, THT 2026 Makes Clear

March 10, 2026

THT 2026: What to Expect in Boston

News Conference News THT 2026

THT 2026: What to Expect in Boston

February 23, 2026

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

News Conference News TCT 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

October 27, 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

Nearly Half of CABG Patients Have New-Onset AF, but It Often Doesn’t Last

News Conference News EACTS 2025

Nearly Half of CABG Patients Have New-Onset AF, but It Often Doesn’t Last

Yael L. Maxwell

October 13, 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

News Conference News ESC 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

Michael O'Riordan

August 31, 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

August 30, 2025

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

News Conference News SCCT 2025

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

Yael L. Maxwell

July 28, 2025

OCT-Guided PCI Bests Angiography in ACS Patients: OCCUPI

News Conference News EuroPCR 2025

OCT-Guided PCI Bests Angiography in ACS Patients: OCCUPI

May 28, 2025

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

News Conference News EuroPCR 2025

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

May 22, 2025

Early TAVI Improves Prognosis in Asymptomatic AS No Matter the Extent of Cardiac Damage

News Conference News EuroPCR 2025

Early TAVI Improves Prognosis in Asymptomatic AS No Matter the Extent of Cardiac Damage

Yael L. Maxwell

May 21, 2025

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

News Conference News ACC 2025

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

Michael O'Riordan

April 04, 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

March 30, 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

March 10, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.